This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, March 1, 2023 Journalist Kelly Crowe and others repeat ...
This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, January 24, 2023 Forty years ago ...
OTTAWA, ON (June 3, 2021): The COVID-19 pandemic has unmasked a dangerous lack of investment in pharmaceutical and vaccine research, development, and ...
Having us do the dirty work of price controls on the U.S.'s behalf is bizarre and pathetic — and dangerous, ...
OTTAWA, ON (December 1, 2020): In a move to protect Canada’s drug supply that has long been recommended by Macdonald-Laurier ...
By determinedly reducing revenues Canada not only ensures the unavailability of existing medications, it sees to it that far fewer ...
The federal government is pursuing an aggressive agenda using untried methods to regulate extremely low drug prices, writes Nigel Rawson. ...
Now more than ever, we should want drug companies to be able to charge high prices, writes Richard Owens in ...
Increased drug revenues enable increased research and development expenditures, which in turn result in better health and longer lives, writes ...
Price-focused regulatory changes could limit access to new drugs and dampen R&D investment, writes Richard Owens. By Richard C. Owens, ...
The federal government is proposing dramatic changes to the pricing of new patented medicines in Canada, and it announced in ...
